Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia-Reference-Cited by-全球学者库

Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia

Published:2020-03-12 Issue:3 Volume:6 Page:e193692
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Shao Zhimin¹,Pang Da²,Yang Hongjian³,Li Wei⁴,Wang Shusen⁵,Cui Shude⁶,Liao Ning⁷,Wang Yongsheng⁸,Wang Chuan⁹,Chang Yuan-Ching¹⁰,Wang Hweichung¹¹,Kang Seok Yun¹²,Seo Jae Hong¹³,Shen Kunwei¹⁴,Laohawiriyakamol Suphawat¹⁵,Jiang Zefei¹⁶,Li Junjie¹,Zhou Julian¹⁷,Althaus Betsy¹⁸,Mao Yixiang¹⁹²⁰,Eng-Wong Jennifer¹⁸

Affiliation:

1. Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

2. Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China

3. Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, China

4. Medicine–Oncology, The First Hospital of Jilin University, Changchun, China

5. Medicine–Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

6. Department of Breast Disease, Henan Cancer Hospital, Zhengzhou, China

7. Department of Breast Disease, Guangdong General Hospital, Guangzhou, China

8. Breast Disease Center, Shandong Cancer Hospital, Jinan, China

9. Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, China

10. Department of General Surgery, Mackay Memorial Hospital, Taipei City, Taiwan

11. Department of Surgery, China Medical University Hospital, Taichung City, Taiwan

12. Department of Hematology–Oncology, Ajou University School of Medicine, Suwon, Republic of Korea

13. Division of Oncology/Hematology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea

14. Breast Disease Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

15. Department of Surgery, Songklanagarind Hospital, Songkhla, Thailand

16. Medicine–Oncology, The Affiliated Hospital of Military Medical Sciences (The 307th Hospital of Chinese People’s Liberation Army), Beijing, China

17. Biometrics, Roche Product Development, Shanghai, China

18. Product Development Oncology, Genentech, Inc, South San Francisco, California

19. Roche Product Development, Shanghai, China

20. now at Oncology Clinical Research, Merck Sharp & Dohme China, Shanghai, China

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2753172/jamaoncology_shao_2019_br_190010.pdf

Reference11 articles.

1. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.;Gianni;Lancet Oncol,2012

2. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).;Schneeweiss;Ann Oncol,2013

3. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.;Swain;Ann Oncol,2018

4. Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: the Nvwa study.;Li;Medicine (Baltimore),2018

5. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.;World Medical Association;JAMA,2013

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore;Expert Review of Pharmacoeconomics & Outcomes Research;2024-01-30

2. Efficacy and safety of first-line therapy in patients with HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials;Journal of Cancer Research and Clinical Oncology;2024-01-20

3. Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study);Gastric Cancer;2024-01-19

4. Optimal choice of neoadjuvant therapy for HER2-positive breast cancer. Analysis of doctors’ preferences in Russian Federation;Medical alphabet;2023-12-03

5. Potential Application of Self-Assembled Peptides and Proteins in Breast Cancer and Cervical Cancer;International Journal of Molecular Sciences;2023-12-02